Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech company, achieved a major milestone when it earned approval for the first CRISPR-based medicine in 2023. However, the company has significantly ...

CRISPR Therapeutics is obviously a biopharma name -- but it's a unique one. Co-founder Emmanuelle Charpentier and her research collaborator Jennifer Doudna co-invented the CRISPR/Cas9 gene-editing ...

The company's innovative qualities may pay rich dividends down the road.

Discover the top CRISPR companies driving innovation in gene editing, from biotech pioneers to promising start-ups shaping the future of medicine and genetics.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

It has also aggressively invested in gene editing, including its 2025 acquisition of cardiovascular disease gene-editing ...

Investing in biotechnology requires a balance between groundbreaking scientific innovation and the realities of clinical development. Choosing between CRISPR Therapeutics (NASDAQ:CRSP) and Viking ...

Looking ahead to 2030, our model projects CRSP could trade at an average price of $254.01, with a potential range between $190.51 and $317.52. This represents a potential 431.6% return from today's ...